Cargando…

Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes

Dual antiplatelet therapy (DAPT) is a foundation of successful coronary artery disease management. DAPT is recommended according to ESC guidelines for 6 months following elective percutaneous coronary intervention and for 12 months following the acute coronary syndrome (ACS). ACS are the most cost-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lesiak, Maciej, Komosa, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802640/ https://www.ncbi.nlm.nih.gov/pubmed/35126547 http://dx.doi.org/10.5114/aic.2021.112082

Ejemplares similares

Significance of antiplatelet therapy in emergency myocardial infarction treatment
por: Komosa, Anna, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome
por: Verdoia, Monica, et al.
Publicado: (2021)

Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
por: Magnani, Giulia, et al.
Publicado: (2023)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
por: Verdoia, Monica, et al.
Publicado: (2020)

Effect of acute coronary syndrome patients’ education on adherence to dual antiplatelet therapy
por: El-Toukhy, Hassan, et al.
Publicado: (2017)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

International patterns of dual antiplatelet therapy duration after acute coronary syndromes
por: Bueno, Héctor, et al.
Publicado: (2017)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Platelet Reactivity in Hepatitis C Virus–Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome
por: Scudiero, Fernando, et al.
Publicado: (2020)

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
por: Tersalvi, Gregorio, et al.
Publicado: (2020)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Tubek, Stanisław, et al.
Publicado: (2021)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
por: Tayeb, Hussam M, et al.
Publicado: (2010)

A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes
por: Alkhalil, Mohammad, et al.
Publicado: (2022)

Evaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome
por: Bonanad, Clara, et al.
Publicado: (2022)

Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome
por: Patti, Giuseppe, et al.
Publicado: (2017)

Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome
por: Jinadu, Tomilola, et al.
Publicado: (2022)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
por: Tam, Chor-Cheung, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome: Practical lessons from a review
por: ten Berg, J. M., et al.
Publicado: (2017)

Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
por: Kao, Chih-Chin, et al.
Publicado: (2021)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis
por: Shpigelman, Jonathan, et al.
Publicado: (2023)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
por: Spinthakis, Nikolaos, et al.
Publicado: (2018)

Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
por: Tatarunas, Vacis, et al.
Publicado: (2020)

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
por: Geng, Xue, et al.
Publicado: (2020)

Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome
por: Parker, William A.E., et al.
Publicado: (2019)

Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor
por: ten Haaf, Monique E., et al.
Publicado: (2023)

Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes
por: De Rosa, Roberta, et al.
Publicado: (2019)

Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence
por: Liga, Riccardo, et al.
Publicado: (2021)

Antiplatelet Therapy for Acute Respiratory Distress Syndrome
por: Chen, Chuan-Mu, et al.
Publicado: (2020)

Triple Therapy Versus Dual Antiplatelet Therapy for Patients with  Atrial Fibrillation and Acute Coronary Syndromes: A Systematic  Literature Review
por: Fake, Aimee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n6im5f1o0pp107qf8enot3bce2